NASHVILLE, Tenn., Oct. 7, 2019 /PRNewswire/ — In response to today’s analyst initiations, SmileDirectClub makes the following statement:
“Today’s market reports reinforce the value of our business model, unit economics and mission to transform smiles through safe, affordable and consumer-first technology to an addressable market of approximately 500 million people worldwide. We remain focused on long term shareholder value – the next 12, 24, 36 months and beyond. Our entrance into the public market allows us to reinvest in innovation, process improvements, international growth and customer experience. Our commitment to our 5,500 team members, our customers and our mission is stronger than ever.”
About SmileDirectClub, Inc.
SmileDirectClub, Inc. (Nasdaq: SDC) is the industry pioneer as the first direct-to-consumer medtech platform for transforming smiles. Through our cutting-edge teledentistry technology and vertically integrated model, we are revolutionizing the oral care industry. By democratizing access to safe, affordable and convenient teeth-straightening solutions, SmileDirectClub’s mission is to unleash the power of people’s smiles to empower them to positively impact their place in the world. SmileDirectClub was founded by Alex Fenkell and Jordan Katzman in partnership with Camelot Venture Group. Available in the U.S., Canada, Australia, and the UK, SmileDirectClub is headquartered in Nashville, Tennessee. For more information, visit SmileDirectClub.com.
Contact: SmileDirectClub Media Relations, press@smiledirectclub.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/statement-from-smile-direct-club-on-analyst-initiations-300933353.html
SOURCE SmileDirectClub, Inc.
Oncovita receives FDA Orphan Drug Designation for its lead oncolytic virus candidate MVdeltaC in the…
Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic…
Annamycin delivering better performance 7th line than would be expected even in 2nd line for…
Glucotrack to present on next-generation continuous blood glucose monitoring technology in Innovation Hub Poster presentation…
Supports late-stage development and scalable manufacturing for LP-310, a non-steroidal oral rinse therapy for Oral…
LOS ANGELES, June 04, 2025 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Expert Market: VDRM), a…